home / stock / oprx / oprx news

OPRX News and Press, OptimizeRx Corporation From 09/20/22

Stock Information
Company Name: OptimizeRx Corporation
Stock Symbol: OPRX
Market: NASDAQ
Website: optimizerx.com
Menu
OPRX OPRX Quote OPRX Short OPRX News OPRX Articles OPRX Message Board
Get OPRX Alerts

News, Short Squeeze, Breakout and More Instantly...
OPRX - OptimizeRx Extends Exclusive Partnership with ePrescribing Leader Therapy Brands

Innovative best-in-class technology solutions continue to offer HCPs a seamless prescribing experience within the EHR workflow ROCHESTER, Mich., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of poi...
OPRX - OptimizeRx to Participate in Upcoming September Conferences

ROCHESTER, Mich., Sept. 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that management will participate in the fol...

OPRX - OptimizeRx Reports Results of Flagship Evidence-Based Physician Engagement Program

Analysis finds patent-pending real-world evidence solution successful in identifying HCPs with patients at risk of non-adherence due to unexpected cost. Proactive affordability messaging key for doctors and patients navigating Medicare coverage gaps ROCHESTER, Mich., Aug. ...

OPRX - SWTX, ALLG and ISPO among mid-day movers

Gainers: Euro Tech Holdings ( CLWT ) +63% . Invitae ( NVTA ) +59% . Allego ( ALLG ) +54% . Grove Collaborative ( GROV ) +52% . BioAtla ( BCAB ) +40% . The Trade Desk ( TTD ) +37% . Chicken Soup for the Soul Entert...
OPRX - OraSure, BioAtla top healthcare gainers; Singular Genomics, OptimizeRx lead losers' pack

Gainers: OraSure Technologies ( OSUR ) +28% . BioAtla ( BCAB ) +24% . Catalyst Pharmaceuticals ( CPRX ) +16% . Clovis Oncology ( CLVS ) +13% . Quanterix ( QTRX ) +13% . Losers: Singular Genomics Systems ( OMIC ...

OPRX - OptimizeRx stock sinks 26% on Q2 miss, while FY22 outlook cut on life sciences sector woes

OptimizeRx ( NASDAQ: OPRX ) stock slumped ~26% premarket on Aug. 10 after Q2 results missed estimates and the company lowered its FY22 outlook, seen below analysts' expectations, citing temporary challenges to life sciences industry. Q2 Non-GAAP EPS declined 60%...

OPRX - OptimizeRx Corporation (OPRX) Q2 2022 Earnings Call Transcript

Image source: The Motley Fool. OptimizeRx Corporation (NASDAQ: OPRX) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: OptimizeRx Corporation (OPRX) Q2 2022 Earnings Call Transcript

OPRX - OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2022 Results - Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q2 2022 Earnings Conference Call August 09, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Da...

OPRX - UPDATE - OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense

Revenue Up 3% to $14.0 million, driven by new customer and program launches Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition Generated $4.4 million in cash flow from operations during the first half of 2022 ...

OPRX - OptimizeRx Q2 Non-GAAP EPS, revenue misses, FY22 guidance below consensus

OptimizeRx press release ( NASDAQ: OPRX ): Q2 Non-GAAP EPS of $0.04 (vs. $0.10 Y/Y) misses by $0.05 . Revenue of $14M (+2.9% Y/Y) misses by $3.06M . For FY22, net revenue is expected to be in the range of of $62M to $68M (vs. consensus of $81.47M) For fur...
Previous 10 Next 10